ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1407	National Cancer Institute	Html	en	Adult Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of adult soft tissue sarcoma.	soft tissue sarcomas 0.852178 adjuvant chemotherapy 0.346182 metastatic soft tissue 0.248446 extremity sarcomas 0.215308 treatment 0.205088 bone sarcoma group 0.220998 soft tissue 0.907283 resectable soft tissue 0.235708 soft-tissue sarcoma 0.237332 Abstract 0.206867	patients 0.337908 Clin Oncol 0.267307 extremity soft tissue 0.314357 adult soft tissue 0.260712 trial 0.209038 radiation therapy 0.357434 local recurrence 0.25142 soft tissue sarcoma 0.709488 high-grade soft tissue 0.212019 Cancer Soft Tissue 0.205799	CLICK HERE
1531	National Cancer Institute	Html	en	Childhood Ependymoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood ependymoma.	cancer treatment 0.626698 recurrent childhood ependymoma 0.554401 following PDQ summaries 0.501476 PDQ cancer information 0.603175 high-grade cancer cells 0.52438 clinical trial search 0.497636 brain tumors 0.624619 Childhood Ependymoma Treatment 0.537776 clinical trials 0.997686 Pediatric Treatment Editorial 0.517454 cancer information summary 0.560017 clinical trial 0.708531 anaplastic ependymoma 0.508455 patients 0.511213 NCI PDQ cancer 0.514722 brain stem 0.532471 radiation therapy 0.873758 Treatment Editorial Board 0.522486 treatment 0.865472 magnetic resonance imaging 0.501265 childhood ependymoma 0.915073 cancer cells 0.900504 standard treatment 0.509266 Cancer Information Service 0.497532 intensity-modulated radiation therapy 0.526143	PDQ Pediatric Treatment 0.501585 Conformal radiation therapy 0.512713 myxopapillary ependymoma 0.509213 treatment clinical trials 0.542772 National Cancer Institute 0.559542 spinal cord 0.912544 tumor cells 0.497383 effects cancer treatment 0.524938 proton-beam radiation therapy 0.524248 new treatment 0.578083 ependymoma forms 0.516544 childhood cancer information 0.507379 childhood brain tumors 0.536709 external radiation therapy 0.570552 treatment clinical trial 0.51013 brain 0.714551 PDQ summary 0.496378 RELA fusion–positive ependymoma 0.556789 cancer clinical trials 0.531786 tumor 0.709426 treatment options 0.516335 cancer information summaries 0.496292 comprehensive cancer information 0.49561 cancer 0.953861	CLICK HERE
1629	National Cancer Institute	Html	en	Penile Cancer Treatment (PDQ®)–Patient Version	Penile cancer is highly curable when found early. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for penile cancer.	cancer treatment 0.320382 biologic therapy 0.30297 Lymph node dissection 0.308565 tissue 0.393322 erectile tissue 0.338087 body 0.324795 PDQ cancer information 0.34528 clinical trial search 0.382837 Penile Cancer Treatment 0.305192 clinical trials 0.721694 cancer information summary 0.319238 clinical trial 0.569243 Recurrent penile cancer 0.32422 patients 0.29378 lymph node biopsy 0.446032 blood vessels 0.32868 sentinel lymph node 0.563667 spongy tissue 0.289271 treatment clinical trial 0.276059 NCI PDQ cancer 0.28258 lymph nodes 0.475166 radiation therapy 0.416871 General information 0.303882 general cancer information 0.275537 treatment 0.454305	wide local excision 0.318281 tumor cells 0.306254 new cancer treatments 0.275369 NCI-supported cancer 0.316489 cancer cells 0.48036 Cancer Information Service 0.276468 penile cancer 0.671625 connective tissue 0.347145 treatment clinical trials 0.301804 National Cancer Institute 0.364819 penis 0.345276 lymph vessels 0.289266 new treatment 0.324645 metastatic penile cancer 0.30082 cancer clinical trials 0.389935 stage 0.320852 tumor 0.326492 cancer information summaries 0.27434 comprehensive cancer information 0.27491 internal radiation therapy 0.325191 cancer 0.921282 information 0.35457 lymph ducts 0.299322 standard treatment 0.273177	CLICK HERE
1828	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda en adultos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda en adultos.	Italy Leukemia Group 0.510748 prognostic factors 0.523487 in adults 0.649162 tirosina cinasa bcr-abl 0.513926 largo plazo 0.507147 leukemia group 0.574628 or fab l3 0.5087 LLA Ph1 0.523666 chronic myeloid leukemia 0.519002 Thiel E 0.520173 TMO autógeno 0.523146 adults with 0.569541 leucemia mielógena 0.512104 donante fraterno 0.513552 lymphocytic leukemia 0.529118 Löffler H 0.510187 LLA recién 0.516678 induction regimen with 0.509327 in adults with 0.545834 patients with 0.533511 complete remission 0.509903 leucemia mielocítica aguda 0.512148 multicenter study 0.514475 adults with standard-risk 0.510496 myeloid leukemia 0.519806	marrow transplantation 0.523773 leucemia aguda 0.509415 leucemia linfoblástica aguda 0.65786 TMO alogénico 0.56508 bone marrow transplantation 0.52273 morfología l3 0.522238 Hoelzer D 0.525554 leukemia with 0.523655 Adult Leukemia Study 0.507091 Northern Italy Leukemia 0.510296 Horowitz MM 0.508541 LLA L3 0.549875 International ALL Trial 0.508909 PDQ Tratamiento 0.509128 Dodge RK 0.508725 Brief-duration high-intensity chemotherapy 0.50796 bone marrow transplant 0.513671 Clin Oncol 0.534506 sistema nervioso central 0.584696 bone marrow 0.527725 with small noncleaved-cell 0.509543 acute lymphoblastic leukemia 0.981898 leukemia with hyper-CVAD 0.507761 lla recidivante quimioterapia 0.519565	CLICK HERE
1850	National Cancer Institute	Html	es	Tratamiento del timoma y carcinoma tímico (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del timoma y carcinoma tímico.	invasive thymic carcinoma 0.2596 timoma tipo 0.753284 Loehrer PJ 0.311974 staging does not 0.262543 current staging does 0.263941 thymic epithelial neoplasms 0.240861 clinicopathologic study 0.267111 thymic epithelial tumors 0.352929 does not predict 0.26201 largo plazo 0.279368 estadio iva 0.280139 classification system reflects 0.276691 Carcinoma tímico mucoepidermoideEste 0.258374 Thorac Oncol 0.241866 clinical study 0.318669 tipo b2 0.255669 Radiat Oncol Biol 0.298534 World Health Organization 0.376953 Thomas CR 0.251437 Loehrer PJ Sr 0.250531 linfocitos t 0.238031 patients with 0.335568 Organization histologic classification 0.322145 tímico papilarEste tipo 0.238335 timoma tipo b1 0.326133	thymoma cases from 0.25857 with completely resected 0.252233 características citológicas 0.238638 thymic carcinoma 0.907691 histologic classification system 0.279611 classification predicts prognosis 0.243585 myasthenia gravis 0.300079 WHO histologic classification 0.270221 unresectable malignant thymomas 0.248319 tipo ab 0.279847 not predict prognosis 0.263382 is correlated with 0.24461 patients with completely 0.257759 Thorac Cardiovasc Surg 0.595787 thymoma with 0.272559 carcinoma basaloide 0.243654 Clin Oncol 0.356331 Oncol Biol Phys 0.300373 estadio iii 0.482375 Health Organization histologic 0.299614 histologic classification 0.363646 Thorac Surg 0.582943 malignant thymoma 0.481068 Toita T 0.262072	CLICK HERE
1882	National Cancer Institute	Html	es	Tratamiento del ependimoma infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del ependimoma infantil.	Hielscher T 0.367784 Grado III 0.497368 prognostic factors 0.418199 Merchant TE 0.351136 Brain Tumor Registry 0.358501 Korshunov A 0.366815 spinal cord ependymomas 0.397087 posterior fossa ependymoma 0.679456 C11orf95-RELA fusions drive 0.339744 líquido cefalorraquídeo 0.413022 infratentorial childhood ependymomas 0.36981 localized ependymoma 0.366693 Radiat Oncol Biol 0.730863 gen rela 0.348774 Pediatric Brain Tumor 0.377851 central nervous system 0.408683 patients with 0.480087 paediatric ependymoma 0.378048 pediatric intracranial ependymoma 0.417211 Acta Neuropathol 0.362477 Mack SC 0.397938 Retrospective Multicohort Analysis 0.345199 cuarto ventrículo 0.34367 United States 0.381387 childhood ependymoma 0.440498	intracranial ependymoma 0.9229 Neuro Oncol 0.422395 pediatric patients with 0.359423 radioterapia posoperatoria 0.479259 Pediatr Blood Cancer 0.435451 myxopapillary ependymoma 0.400108 spinal cord 0.397509 supratentorial ependymoma 0.360521 C11orf95-RELA fusions 0.341174 ependymoma patients with 0.34014 infantil recién 0.356568 Clin Oncol 0.43496 childhood intracranial ependymoma 0.4276 sistema nervioso central 0.476331 with intracranial ependymoma 0.449085 Oncol Biol Phys 0.751374 brain tumor 0.436772 Witt H 0.430118 Grado II 0.78433 patients with localized 0.344179 Central Brain Tumor 0.357242 ependimoma infantil grupo 0.387504 Childs Nerv Syst 0.378828 Brain Tumor Consortium 0.35913	CLICK HERE
1966	National Cancer Institute	Html	es	Tratamiento del cáncer de labio y de cavidad oral (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de labio y de cavidad oral.	medicamentos retinoides 0.568081 siguientes procedimientos 0.97932 siguientes elementos 0.624752 estadio ii 0.723086 rayos x 0.572217 pequeñas marcas 0.537003 estadio ivc 0.583451 necesarios implantes 0.546577 siguientes riesgos 0.500736 malla ayuda 0.53799 Instituto Nacional 0.536147 área pequeña detrás 0.642422 presente sección 0.536306	partes distantes 0.555475 Physician Data Query 0.531283 estadio iii 0.581263 libre uso 0.500877 radioterapia hiperfraccionada 0.899395 cáncer.ampliar radioterapia 0.670655 Cancer Institute 0.499502 siguientes enlaces 0.516515 siguientes pruebas 0.617318 Dientes flojos 0.587562 pequeño espejo 0.576408 siguientes estadios 0.58645	CLICK HERE
3429	National Cancer Institute	Html	es	Agua fluorada	Hoja informativa que examina los estudios realizados sobre la posible conexión entre el agua fluorada y el cáncer.	Villanacci JF 0.447057 Feltbower RG 0.446597 fluoruro ingerido 0.954566 Mortality Weekly Report 0.483586 vasta cantidad 0.449716 carcinogenicity studies with 0.478781 bajas. Muchos estudios 0.468962 Water Fluoridation Statistics 0.487645 Toxicology Program rodent 0.480514 Napier TS 0.445775 Ewing sarcoma diagnosed 0.483942 Great Britain 0.443018 Disease Control 0.536557 public drinking water 0.505168 National Academy 0.558901 Instituto Nacional 0.520062 agua ayuda 0.629089 Environmental Health 0.58081 Related Programs 0.449277 Estados Unidos 0.666074 Kim FM 0.441491 resultados contradictorios 0.444365 Ingested Fluoride 0.54922 PubMed Abstract 0.93552	among 0-49-year-olds 0.445423 Williams PL 0.44275 salud pública 0.65032 Ad Hoc Subcommittee 0.477798 International Journal 0.533052 Blakey K 0.445319 Dental Research 0.46834 Parslow RC 0.444263 Health Effects 0.572713 Grand Rapids 0.447598 Hejtmancik MR 0.446466 Environmental Health Sciences 0.528481 Hayes C 0.441487 Toft JD 0.447997 drinking water 0.564502 public health 0.755217 National Institute 0.45889 Coordinate Environmental Health 0.506784 prevent dental caries 0.542747 Retrieved August 0.565765 Salud Ambiental 0.441563 National Research Council 0.675505 siglo xx 0.446805 Public Health Service 0.715782	CLICK HERE
3600	National Cancer Institute	Html	en	NCI-COG Pediatric MATCH	In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have certain genetic mutations will be treated with drugs that are matched to those mutations.	histiocytoses—whose cancer 0.377277 genetic makeup 0.401588 university medical centers 0.467884 brain tumors 0.440585 blood sample 0.480719 clinical trials 0.534239 additional genetic testing 0.511528 patients 0.666156 new treatment arms 0.480309 visit NCI 0.372109 solid tumors 0.469802 open treatment arms 0.478804 tumor sample 0.358797 Children’s Oncology 0.616646 genomic sequencing 0.508758 pediatric oncologist 0.373126 genetic changes 0.973154 precision medicine 0.370826 Hereditary genetic changes 0.524899 certain drugs 0.381989 screening step 0.630676 laboratory method 0.368599 Pediatric MATCH 0.671874 NCI-COG Pediatric MATCH 0.543169 specific targeted drugs 0.540831	nationwide cancer treatment 0.58381 cancer cells 0.393101 Cancer Information Service 0.476816 pediatric patients 0.406357 genetic counseling 0.384583 Clinical Trials Network 0.452506 enrollment steps 0.358937 treatment arm 0.797992 pediatric cancers 0.526249 experimental drugs 0.379128 genetic change 0.798918 study drugs 0.381585 contact NCI 0.380025 health insurance plans 0.447587 specific genetic changes 0.498204 experimental treatment 0.509457 certain genetic changes 0.509656 cancer centers 0.372633 cancer site 0.501146 clinical trials search 0.454345 tumors 0.675099 cancer information specialists 0.479605 Oncology Group 0.642399 standard treatment 0.375977	CLICK HERE
3604	National Cancer Institute	Html	null	Advancing Precision Medicine in Oncology	Multiyear funding for the Precision Medicine Initiative® (PMI) will help accelerate progress toward the promising new era of precision medicine in oncology.			CLICK HERE